American Heart Journal
Volume 154, Issue 1 , Pages 3-11, July 2007

Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs

  • Steven R. Steinhubl, MD

      Affiliations

    • Gill Heart Institute, University of Kentucky, Lexington, KY
    • Corresponding Author InformationReprint requests: Steven R. Steinhubl, MD, The Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky College of Medicine, 900 S. Limestone St., 326 C. T. Wethington Bldg., Lexington, KY 40536-0284.
    • ,
  • Adnan Kastrati, MD

      Affiliations

    • Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    • ,
  • Peter B. Berger, MD

      Affiliations

    • Geisinger Medical Center, Danville, PA

Received 26 January 2007; accepted 1 April 2007. published online 23 May 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Disclosures: Dr Steinhubl received research support from and served as a consultant for Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company and served as a consultant for AstraZeneca. Doctor Berger received consulting and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Johnson & Johnson, Genentech, Guilford, Arginox, Schering-Plough, and Boston Scientific and is the medical director and owns equity in Lumen. Doctor Kastrati received lecture fees from Bristol-Myers Squibb, Lilly, and Sanofi-Aventis.

 Disclosures: Financial and editorial support for this publication has been provided by Sanofi-Aventis US Inc.

PII: S0002-8703(07)00287-6

doi:10.1016/j.ahj.2007.04.009

American Heart Journal
Volume 154, Issue 1 , Pages 3-11, July 2007

Article Tools

* Image Usage & Resolution